NDC properties for "AndroGel 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT" (RxCUI 1597075)
About this data
The tables show NDC propoerties for AndroGel 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT with the RxCUI 1597075
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for AndroGel 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT (RxCUI 1597075)
| MMSL_CODE | BD26943 |
|---|---|
| NDA | NDA022309 |
| RxCUI | 1597075 |
| SPL_SET_ID | 8677ba5b-8374-46cb-854c-403972e9ddf3 |
| SPL_SET_ID | f4e8d29b-8707-4d47-e053-2a95a90aecee |
| Prescribable Synonym | AndroGel 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT |
| RXNAV_STR | AndroGel 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT |
| RxNorm Name | 60 ACTUAT testosterone 20.25 MG/ACTUAT Topical Gel [Androgel] |
| RxNorm Synonym | AndroGel 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT |
| Related queries | Interactions (for RxCUI 1597075) |
NDC Properties
NDC Item 00051846233
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-33 |
| NDC Item | 00051846233 |
| Packaging | 1 BOTTLE, PUMP in 1 CARTON (0051-8462-33) / 88 g in 1 BOTTLE, PUMP |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 17139056288
| NDC 9 | 17139-562 |
|---|---|
| NDC 10 | 17139-562-88 |
| NDC Item | 17139056288 |
| Packaging | 1 BOTTLE, PUMP in 1 CARTON (17139-562-88) / 88 g in 1 BOTTLE, PUMP |
| DCSA | CIII |
| FDA SPL set id | 756537 |
| Labeler | ASCEND Therapeutics U.S., LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2023-02-17 |
| Marketing status | ACTIVE |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 17139-562 |
NDC Item 00051846233
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-33 |
| NDC Item | 00051846233 |
| Packaging | 1 BOTTLE, PUMP in 1 CARTON (0051-8462-33) / 88 g in 1 BOTTLE, PUMP |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 17139056288
| NDC 9 | 17139-562 |
|---|---|
| NDC 10 | 17139-562-88 |
| NDC Item | 17139056288 |
| Packaging | 1 BOTTLE, PUMP in 1 CARTON (17139-562-88) / 88 g in 1 BOTTLE, PUMP |
| DCSA | CIII |
| FDA SPL set id | 756537 |
| Labeler | ASCEND Therapeutics U.S., LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2023-02-17 |
| Marketing status | ACTIVE |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 17139-562 |